| Followers | 310 |
| Posts | 77829 |
| Boards Moderated | 4 |
| Alias Born | 02/16/2008 |
Tuesday, July 26, 2016 6:30:53 PM
Fate,Regenerative Medicine Market: Key Players
"Some of the key participating global players in regenerative medicine market are OncoMed Pharmaceuticals, BrainCells, Five Prime Therapeutics, Pieris AG, Tyrx Pharma, Aldagen, Histogenics,
Fate Therapeutics, iZumi Bio, Neurologix, Inc., Cellerant Therapeutics, Inc., Stem Cell Sciences plc., Cellerant Therapeutics, Inc., Embryome Sciences, Inc., Chromos Molecular Systems, Aastrom Biosciences, BioRestorative, Dendreon, Histogenics, Nanotope, Cell Medica, RTI Surgical, Neuralstem, Fate Therapeutics and others."
http://www.openpr.com/news/351265/Market-Forecast-Report-on-Regenerative-Medicine-2016-2026.html
"Some of the key participating global players in regenerative medicine market are OncoMed Pharmaceuticals, BrainCells, Five Prime Therapeutics, Pieris AG, Tyrx Pharma, Aldagen, Histogenics,
Fate Therapeutics, iZumi Bio, Neurologix, Inc., Cellerant Therapeutics, Inc., Stem Cell Sciences plc., Cellerant Therapeutics, Inc., Embryome Sciences, Inc., Chromos Molecular Systems, Aastrom Biosciences, BioRestorative, Dendreon, Histogenics, Nanotope, Cell Medica, RTI Surgical, Neuralstem, Fate Therapeutics and others."
http://www.openpr.com/news/351265/Market-Forecast-Report-on-Regenerative-Medicine-2016-2026.html
Recent FATE News
- Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences • GlobeNewswire Inc. • 04/09/2026 01:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed • GlobeNewswire Inc. • 03/18/2026 03:30:00 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/04/2026 09:05:00 PM
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 09:05:00 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (US) • 03/03/2026 03:02:00 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (Canada) • 03/03/2026 03:02:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:07:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 02:04:07 PM
- Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates • GlobeNewswire Inc. • 02/26/2026 02:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets • PR Newswire (US) • 01/26/2026 03:16:00 PM
- Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets • PR Newswire (Canada) • 01/26/2026 03:16:00 PM
- Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets • GlobeNewswire Inc. • 01/23/2026 05:56:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:03:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:00:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:04:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:03:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/09/2026 08:08:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/09/2026 08:08:01 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/05/2026 09:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/29/2025 07:44:28 PM
- Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs • GlobeNewswire Inc. • 12/08/2025 01:00:00 PM
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/25/2025 01:00:00 PM

